How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Document

    Has all of the relevant evidence been taken into account?

  • Question on Document

    Are the summaries of clinical and cost effectiveness reasonable interpretations of the evidence?

  • Question on Document

    Are the recommendations sound and a suitable basis for guidance to the NHS?

  • Question on Document

    Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of age, disability, gender reassignment, pregnancy and maternity, race, religion or belief, sex or sexual orientation?
The content on this page is not current guidance and is only for the purposes of the consultation process.

Rucaparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy

Closed for comments This consultation ended on at   Request commenting lead permission

2 Information about rucaparib

Marketing authorisation indication

2.1

Rucaparib (Rubraca, pharma&) is indicated 'as monotherapy for the maintenance treatment of adult patients with advanced (FIGO Stages III and IV) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy'.

Price

2.3

The list price for rucaparib is £3,562.00 per 60‑tablet pack of 300 mg, 250 mg or 200 mg tablets (excluding VAT; BNF online, accessed May 2024). The company estimates that the average cost per year of rucaparib is £105,869 (estimated from the deterministic base-case economic analysis using the list price).

2.4

The company has a commercial arrangement (simple discount patient access scheme). This makes rucaparib available to the NHS with a discount. The size of the discount is commercial in confidence.